Oragenics Inc is engaged in the healthcare sector. The firm is focused on becoming a leader in developing novel antibiotics against infectious diseases and on developing effective treatments for oral mucositis. Oragenics involves developing its antibiotic product candidate, OG716 as well as other ho... Oragenics Inc is engaged in the healthcare sector. The firm is focused on becoming a leader in developing novel antibiotics against infectious diseases and on developing effective treatments for oral mucositis. Oragenics involves developing its antibiotic product candidate, OG716 as well as other homolog antibiotic product candidates, researching LBPs, and having other product candidates, including SMaRT Replacement Therapy positioned for out-licensing or partnering. It is also developing a Terra CoV-2 immunization product candidate to combat the novel coronavirus. 詳細を表示
SARASOTA, Fla., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments for brain-related health conditions, announced it will be...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.06 | -17.6470588235 | 0.34 | 0.35 | 0.2542 | 1158961 | 0.31195893 | CS |
4 | -0.0641 | -18.6283057251 | 0.3441 | 0.43 | 0.2542 | 637966 | 0.33777557 | CS |
12 | -0.75 | -72.8155339806 | 1.03 | 1.29 | 0.2542 | 539675 | 0.41135954 | CS |
26 | -2.82 | -90.9677419355 | 3.1 | 3.2 | 0.2542 | 541755 | 0.97744848 | CS |
52 | -3.27 | -92.1126760563 | 3.55 | 7.74 | 0.2542 | 316823 | 1.12428732 | CS |
156 | -33.92 | -99.1812865497 | 34.2 | 37.50594 | 0.2542 | 447743 | 17.32567275 | CS |
260 | -29.24 | -99.0514905149 | 29.52 | 127.2 | 0.2542 | 3040244 | 49.29884131 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約